A PYMNTS Company

US: FTC staff recommends approval of Roche deal for Spark

By  |  October 27, 2019

The Federal Trade Commission staff reviewing Roche’s plan to buy US-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the US company, acquiring a portfolio that includes a blindness treatment that has US and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.